Is RANKL inhibition both anti-resorptive and anabolic in rheumatoid arthritis?. Issue 1 (December 2015)

• Record Type: Journal Article
• Authors: Sims, Natalie; Romas, Evange
• Is Part Of: Arthritis research & therapy. Volume 17:Issue 1(2015)
• Page Start: 1
• Page End: 2
• Publication Date: 2015-12
• Subjects: Arthritis -- Periodicals; Arthritis -- Treatment -- Periodicals; 616.722005
• DOI: 10.1186/s13075-015-0861-5
• Languages: English
• ISSNs: 1478-6362

Abstract

Abstract A small peptide, OP3-4, blocks receptor activator of NF-κB from binding to its ligand, receptor activator of NF-κB ligand (RANKL), and was reported recently to inhibit bone resorption, promote bone formation and protect cartilage in a preclinical rheumatoid arthritis model. The latter effects may result from inhibition of RANKL reverse signalling in osteoblasts and chondrocytes. Whether other RANKL inhibitors, such as denosumab, share this action is not known, but OP3-4 at least has potential to provide anabolic treatment for both systemic and focal bone loss in inflammatory arthritis.